We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gold-Based HDL-Nanoparticles Kill Lymphoma Cells without Drugs

By LabMedica International staff writers
Posted on 07 Feb 2013
Synthetic nanoparticles that mimic the look and behavior of HDLs (high-density lipoproteins) have been found to act as potent killers of human B-cell lymphoma cells both in cultures and in a mouse model without the necessity of associated anticancer drugs.

Investigators at Northwestern University (Chicago, IL, USA) synthesized HDL biomimetic nanoparticles capable of binding cholesterol. More...
These structures used a gold nanoparticle core as template for the assembly of a mixed phospholipid layer that adsorbed and intercalated molecules of apolipoprotein A-I. These synthesized structures had the general size and surface composition of natural HDL and, importantly, were able to bind free cholesterol.

Some cancer cells express receptors for HDLs due to their increased need for cholesterol. Accordingly, HDL-nanoparticles could be used as vehicles to deliver therapeutic agents to cancer cells expressing these HDL receptors. Moreover, a surprising study published in the January 23, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) revealed that the HDL-nanoparticles by themselves were toxic to B-cell lymphoma cells without the necessity of associated anticancer drugs.

Like natural HDLs, the biomimetic HDL-nanoparticles targeted scavenger receptor type B-1, a high-affinity HDL receptor expressed by lymphoma cells. Use of the gold nanoparticle template enabled differential manipulation of cellular cholesterol flux, promoting transport of cholesterol away from the cells while limiting cholesterol delivery to the cells. This combination of scavenger receptor type B-1 binding and relative cholesterol starvation selectively induced apoptosis and ultimately death of the cancer cells.

In mice bearing B-cell lymphoma xenografts, treatment with HDL-nanoparticles selectively inhibited tumor growth.

"This has the potential to eventually become a nontoxic treatment for B-cell lymphoma, which does not involve chemotherapy," said contributing author Dr. Leo I. Gordon, professor of hematology and oncology at Northwestern University. "It is an exciting preliminary finding."

The investigators reported being particularly encouraged by early data showing that the HDL nanoparticles did not appear to be toxic to other human cells normally targeted by HDLs, normal human lymphocytes, or to mice.

Related Links:
Northwestern University




Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.